Drug
Valganciclovir clinical trials
Also written Valcyte.
- studies test it
- 76
- open now
- 7
- in phase 3
- 26
- first study started
- 1997
Keep track of what changes. Save the Valganciclovir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
74 studies that test it; most in 2004 (8)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 8 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 29
- Phase 3
- 26
- Phase 4
- 13
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 56
Hoffmann-La Roche (11) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · University of California, San Francisco (4) · National Cancer Institute (NCI) (2) · Dr. Ann C.T.M. Vossen (2) · Dr. Reddy's Laboratories Limited (2) · University of Washington (2) · Washington University School of Medicine (2)
Often tested with
Tested in the same studies.
Ganciclovir (10) · Zidovudine (2) · Bortezomib (2) · Valacyclovir (2) · Brincidofovir (2) · Arginine butyrate (2) · Everolimus (2) · Etoposide (1)
Studies
Open first, then newest update. How each study uses Valganciclovir is read from its arms, and is right about nine times in ten.
Testing it · 76
- Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R RecipientsRecruitingPhase 3University of California, San FranciscoNCT06798909Written as Valganciclovir (Pre-emptive CMV Therapy)
- Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and IINot yet recruitingPhase 2University of California, San FranciscoNCT07513623Written as Valganciclovir
- Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV InfectionRecruitingPhase 2The Methodist Hospital Research InstituteNCT07383649Written as Valganciclovir
- CMV Immunity Monitoring in Lung Transplant RecipientsRecruitingPhase 2NYU Langone HealthNCT05708755Written as Valganciclovir
- ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAseNot yet recruitingPhase 2Wits Health Consortium (Pty) LtdNCT07379203Written as Valganciclovir
- Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsRecruitingPhase 4First Affiliated Hospital Xi'an Jiaotong UniversityNCT07266467Written as Valganciclovir
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With GlioblastomaRecruitingPhase 1/2Rznomics, Inc.NCT06102525Written as VGCV
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00092222Written as Valganciclovir
- Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired InfantsTerminatedPhase 2Albert ParkNCT03107871Written as Valganciclovir
- ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSIONCompletedPhase 1/2Laureate Institute for Brain Research, Inc.NCT04724447Written as Valganciclovir
- Phase 1 Study of GEN2 in Patients With Advanced Solid TumorsTerminatedPhase 1GenVivo, Inc.NCT06391918Written as GEN2 + Valganciclovir
- Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment OutcomesTerminatedPhase 2/3University of California, San FranciscoNCT03586284Written as Valganciclovir Hydrochloride
- A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma PatientsActive, not recruitingPhase 2Cecilia Soderberg-NauclerNCT04116411Written as Valganciclovir Tablets
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaCompletedPhase 2/3Hospital Universitario 12 de OctubreNCT03915366Written as Valganciclovir Oral Solution [Valcyte]
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesCompletedPhase 1/2Viracta Therapeutics, Inc.NCT03397706Written as VRx-3996 and valganciclovir
- Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing LossCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01649869Written as Valganciclovir
- Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung TransplantationCompletedPhase 3Duke UniversityNCT00227370Written as valganciclovir
- Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab TherapyTerminatedPhase 3Centre Hospitalier Universitaire de Saint EtienneNCT04064697Written as Valganciclovir
- Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.CompletedPhase 3Maimónides Biomedical Research Institute of CórdobaNCT03699254Written as Valganciclovir
- Asymptomatic Congenital CMV TreatmentTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03301415Written as Valganciclovir
See all 76 studies that test Valganciclovir →
Given in every arm · 7 — Valganciclovir is usual care beside what is tested
- Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant RecipientsRecruitingPhase 4University Health Network, TorontoNCT07235683Written as Valganciclovir/Ganciclovir
- Letermovir-based Dual Therapy for Treatment of Cytomegalovirus InfectionsRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT06334497Written as Valganciclovir
- EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07138989Written as Valganciclovir Hydrochloride Tablets
- Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCTerminatedPhase 1Viracta Therapeutics, Inc.NCT05166577Written as Valganciclovir
- Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseCompletedPhase 2National Cancer Institute (NCI)NCT01441063Written as Valganciclovir (VGC)
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus InfectionCompletedPhase 4Medical University of South CarolinaNCT01509404Written as Valganciclovir
- Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) TransplantationCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00141037Written as Valganciclovir
As the comparator · 8 — what is tested is compared with Valganciclovir
- Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart TransplantRecruitingPhase 2/3Columbia UniversityNCT07079735Written as Valganciclovir
- Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot StudyRecruitingNot applicableNational Taiwan University HospitalNCT07294547Written as Valganciclovir (Valcyte)
- Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant RecipientsCompletedPhase 4Medical University of South CarolinaNCT06034925Written as Valganciclovir
- Letermovir for CMV Prevention After Lung TransplantationCompletedPhase 2Fernanda P Silveira, MD, MSNCT05041426Written as Valganciclovir
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)CompletedPhase 3Merck Sharp & Dohme LLCNCT03443869Written as Valganciclovir
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsCompletedPhase 3ShireNCT02927067Written as Valganciclovir
- ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney TransplantationCompletedPhase 2University of MinnesotaNCT01972035Written as Valganciclovir
- Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or CidofovirCompletedPhase 3ShireNCT02931539Written as Valganciclovir
Codes
What other systems call Valganciclovir · ClinicalTrials.gg INT006757
- MeSH (NLM) D000077562ValganciclovirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) GCU97FKN3RVALGANCICLOVIRConfirmed FDA, NLM, Wikidata
- RxNorm 275891Confirmed FDA, Wikidata
- Wikidata Q423384valganciclovirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2629ValganciclovirConfirmed FDA, Wikidata
- DrugBank DB01610One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077562 | Valganciclovir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | GCU97FKN3R | VALGANCICLOVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 275891 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423384 | valganciclovir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2629 | Valganciclovir | Confirmed FDA, Wikidata |
| DrugBank | DB01610 | — | One source Wikidata |
Also registered as valganciclovir hydrochloride (UNII 4P3T9QF9NZ · RxNorm 283815).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.